Compare Digital Realty Trust, Inc. (DLR) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Digital Realty Trust, Inc. vs Viatris Inc — how do they compare? Digital Realty Trust, Inc. trades at $178.53 (market cap $65.32B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Digital Realty Trust, Inc. is far larger — about 3.3× Viatris Inc's market cap, and Digital Realty Trust, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals — on Pluang, investors hold Digital Realty Trust, Inc. for 93 Days and Viatris Inc for 57 Days on average.
| DLR | VTRS | |
|---|---|---|
Market Cap | $65.32B | $20.03B |
Volume | 2,563,950 | 14,109,977 |
Sector | Real Estate | Health |
52-Week High | $203.91 | $18.27 |
52-Week Low | $147.93 | $9.74 |
Typical Hold Time | 93 Days | 57 Days |
Enterprise Value | $84.03B | $32.15B |
Dividend Yield | 2.77% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Digital Realty Trust (DLR) trades at $178.15, down 1.29% with a bearish technical outlook. The stock shows strong fundamentals with Q2 2026 EPS beating expectations at $1.21 versus $0.48 expected, and revenue growth from $6.11B in 2025 to projected $6.8B in 2026. Analyst consensus is strongly bullish with 34 buys and a $222.35 price target, supported by AI-driven data center demand and recent infrastructure expansions.
DLR presents a compelling growth opportunity driven by AI infrastructure demand, with record interconnection activity and strategic partnerships. Key risks include high valuation multiples (P/E 85.89) and significant capital expenditures. The technical bearish signal contrasts with strong fundamental momentum, creating potential for volatility near-term.
Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.
The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Digital Realty Trust, Inc.
Digital Realty owns and operates nearly 300 data centers worldwide. It has more than 35 million rentable square feet across five continents. Digital's offerings range from retail co-location, where an enterprise may rent a single cabinet and rely on Digital to provide all the accommodations, to cold shells, where hyperscale cloud service providers can simply rent much, or all, of a barren, power-connected building. In recent years, Digital Realty has de-emphasized cold shells and now primarily provides higher-level service to tenants, which outsource their related IT needs to Digital. Digital Realty has also moved more into the co-location business, increasingly serving enterprises and facilitating network connections. Digital Realty operates as a real estate investment trust.
Read more on DLR →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
